dr peter attia semaglutide Attia: Our conversation about his hit book OUTLIVE, Medicine 3.0, promoting healthspan, GLP-1 drugs and more Semaglutide Insights | Ask Huberman

The participants were offered an open-label extension with high-dose gantenerumab because of its positive effects on imaging and other biomarkers, such as normalized CSF A42, and because it reduced CSF total tau and pTau181 levels

A patient on naltrexone for opioid disorder may have underlying metabolic dysfunction, cardiovascular risk, or psychiatric comorbidities that influence GLP-1 therapy safety and efficacy

[1] [2] For diabetes, it's marketed as Ozempic (injectable, up to 2 mg weekly) and Rybelsus (oral, 7-14 mg daily)

On Medical Weight Loss and Wellness Med spas have seen the medical weight loss market explode in the last five years

Of course, if its a medical emergency, patients should call 911 or go to their local hospital, as everything is done virtually